Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Robert M. Straubinger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0870-9236; OpenAlex author ID A5057883761. Sources: OpenAlex.

Their work

Papers
33 (first author 4, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: 6 papers · 2019: 2 papers · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 6 papers · 2025: 1 paper

Papers 33

  1. Magnetic chromatography improves colloidal and MRI attributes of magnetoliposomes enabling evaluation of the impact of size on bio-distribution in an in vivo m… Co-author DOI 10.1039/d4tb02219j↗
  2. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness. Last author DOI 10.1016/j.drup.2024.101064↗
  3. Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models. Last author DOI 10.1016/j.xphs.2023.10.019↗
  4. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Signal Transduction Pathways Related to Tu… Co-author DOI 10.1016/j.xphs.2023.10.030↗
  5. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathw… Co-author DOI 10.1016/j.xphs.2023.10.036↗
  6. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors … Last author DOI 10.1111/bph.16289↗
  7. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. Last author DOI 10.1158/1078-0432.ccr-23-0131↗
  8. Species-Deconvolved Proteomics for In Situ Investigation of Tumor-Stroma Interactions after Treatment of Pancreatic Cancer Patient-Derived Xenografts with Comb… Co-author DOI 10.1021/acs.jproteome.3c00164↗
  9. Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces… Co-author DOI 10.1021/acs.jproteome.3c00463↗
  10. Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Der… Co-author DOI 10.3390/life13030608↗
  11. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.1016/j.mcpro.2022.100409↗
  12. FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. Co-author DOI 10.1208/s12248-022-00752-8↗
  13. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Last author DOI 10.1124/jpet.120.000412↗
  14. DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. Co-author DOI 10.1016/j.jconrel.2020.05.046↗
  15. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant… Co-author DOI 10.1038/s41416-020-01046-6↗
  16. Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells. Last author DOI 10.1186/s12885-020-07398-9↗
  17. Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. Co-author DOI 10.3390/ijms21030962↗
  18. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Co-author DOI 10.1097/coc.0000000000000492↗
  19. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model. Last author DOI 10.1158/1535-7163.mct-18-0354↗
  20. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. Co-author DOI 10.1002/psp4.12320↗
  21. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts. Co-author DOI 10.1007/s10928-018-9603-z↗
  22. Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonS… Co-author DOI 10.1074/mcp.ra117.000519↗
  23. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-2262↗
  24. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Co-author DOI 10.3389/fphar.2018.00084↗
  25. A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts. Co-author DOI 10.3390/proteomes6040045↗
  26. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Co-author DOI 10.1007/s00280-015-2907-4↗
  27. Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model. Last author DOI 10.1158/1535-7163.mct-15-0602↗
  28. Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells. Co-author DOI 10.3389/fphar.2016.00421↗
  29. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. First author DOI 10.1007/s10928-015-9429-x↗
  30. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models. Co-author DOI 10.1038/bjc.2013.754↗
  31. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. First author DOI 10.1007/s00280-013-2117-x↗
  32. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. First author DOI 10.1007/s00280-013-2226-6↗
  33. Interactions of everolimus and sorafenib in pancreatic cancer cells. First author DOI 10.1208/s12248-012-9417-7↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jun Qu · 11 shared papers, 2018–2024 · strength 1.94
  2. William J. Jusko · 13 shared papers, 2013–2024 · strength 1.47
  3. Qingxiang Lin · 6 shared papers, 2021–2024 · strength 1.19
  4. Tista Roy Chaudhuri · 5 shared papers, 2016–2025 · strength 1.07
  5. Wen Wee Ma · 7 shared papers, 2016–2024 · strength 1.06
  6. Jin Niu · 5 shared papers, 2018–2024 · strength 0.82
  7. Martin M. Clynes · 6 shared papers, 2018–2024 · strength 0.73
  8. Xin Miao · 4 shared papers, 2016–2024 · strength 0.60
  9. Sandra Roche · 5 shared papers, 2018–2023 · strength 0.54
  10. Xue Wang · 3 shared papers, 2018–2024 · strength 0.53
  11. Sailee Suryakant Rasam · 2 shared papers, 2022–2023 · strength 0.39
  12. Michelle K. Greene · 3 shared papers, 2020–2024 · strength 0.37
  13. Christopher J. Scott · 3 shared papers, 2020–2024 · strength 0.37
  14. Jun Wang · 2 shared papers, 2020–2024 · strength 0.37
  15. Dermot F. Brougham · 1 shared paper, 2025 · strength 0.37
  16. Cara Moloney · 1 shared paper, 2025 · strength 0.37
  17. Xu Zhu · 3 shared papers, 2015–2018 · strength 0.31
  18. Kevin C. Conlon · 3 shared papers, 2018–2023 · strength 0.30
  19. Fiona O’Neill · 3 shared papers, 2018–2023 · strength 0.30
  20. Taylor J. Allen-Coyle · 2 shared papers, 2022–2023 · strength 0.30
  21. Finbarr O’Sullivan · 2 shared papers, 2022–2023 · strength 0.30
  22. Ray McDermott · 2 shared papers, 2020–2023 · strength 0.23
  23. Paula Meleady · 2 shared papers, 2018–2023 · strength 0.21
  24. Xue Wang · 1 shared paper, 2020 · strength 0.15
  25. Alex A. Adjei · 2 shared papers, 2014–2019 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.